

*AMENDMENTS TO THE CLAIMS*

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (Currently Amended) A liposome encapsulating a water-soluble substance in an internal cavity thereof, wherein the liposome ~~which~~ has a particle size of 300 nm or less and contains a triglycerol.
2. (Previously Presented) The liposome according to claim 1, which has a particle size of 200 nm or less.
3. (Previously Presented) The liposome according to claim 1, wherein an encapsulation rate of the water-soluble compound in the internal cavity is 60% or higher.
4. (Previously Presented) The liposome according to claim 1, wherein an encapsulation rate of the water-soluble compound in the internal cavity is 70% or higher.
5. (Previously Presented) The liposome according to claim 1, wherein the water-soluble substance is a water-soluble low molecular weight compound, a protein, a nucleic acid, a polysaccharide, and/or an indicator.
6. (Previously Presented) The liposome according to claim 1, wherein the water-soluble substance is a water-soluble low molecular weight compound and a polysaccharide.
7. (Previously Presented) The liposome according to claim 1, wherein the water-soluble substance is a water-soluble low molecular weight compound.
8. (Previously Presented) The liposome according to claim 5, wherein the water-soluble low molecular weight compound is nedaplatin, cisplatin, carboplatin, gemcitabine, or Ara-C.

9. (Previously Presented) The liposome according to claim 5, wherein the polysaccharide is a chitosan derivative, or a polysaccharide having carboxyl group.

10. (Previously Presented) The liposome according to claim 9, wherein the polysaccharide having carboxyl group is carboxymethylcellulose, hyaluronic acid, chondroitin, or chondroitin sulfate.

11. (Previously Presented) The liposome according to claim 1, wherein the triglycerol is triolein.

12. (Currently Amended) The liposome according to claim 1, ~~wherein which~~ contains a ligand and/or a water-soluble synthetic polymer is bound to a surface of the liposome.

13. (Currently Amended) The liposome according to claim 1, ~~which contains~~ wherein a ligand is bound to a surface of the liposome.

14. (Previously Presented) The liposome according to claim 12, wherein the ligand binds to a target cell or a target molecule.

15. (Previously Presented) The liposome according to claim 12, wherein the ligand is an antibody or an antibody fragment.

16. (Previously Presented) The liposome according to claim 12, wherein the water-soluble synthetic polymer is selected from the group consisting of polyalkylene glycol, polylactic acid, polyglycolic acid, polyvinylpyrrolidone, and a copolymer of vinylpyrrolidone and maleic anhydride.

17. (Previously Presented) The liposome according to claim 12, wherein the water-soluble synthetic polymer is polyalkylene glycol.

18. (Previously Presented) The liposome according to claim 16, wherein the polyalkylene glycol is polyethylene glycol.

19. (Previously Presented) The liposome according to claim 12, wherein the ligand and/or the water-soluble synthetic polymer binds only to an external surface of the liposome.

20. (Previously Presented) A pharmaceutical composition containing the liposome according to claim 1.

21. (Previously Presented) An agent for diagnosis and/or therapeutic treatment of a cancer, which comprises the liposome according to claim 1.

22. (New) The liposome according to claim 1, which is manufactured by the following steps:

(a) dissolving a phospholipid and a triglycerol in a water-immiscible organic solvent, and mixing the resulting solution with an aqueous solution of a medicament,

(b) emulsifying the mixture to prepare a W/O emulsion with a particle size of 10 to 150 nm,

(c) adding the W/O emulsion in an aqueous phase with stirring to form a double emulsion, and

(d) removing the organic solvent from the double emulsion.

23. (New) The liposome according to claim 22, wherein the particle size of the W/O emulsion is 30 to 100 nm.

24. (New) The liposome according to claim 22, wherein the step (a) further comprises dissolving cholesterol in the water-immiscible organic solvent.

25. (New) A method of producing a liposome, which comprises the following steps:

(a) dissolving a phospholipid and a triglycerol in a water-immiscible organic solvent, and mixing the solution with an aqueous solution of a medicament.

(b) emulsifying the mixture to prepare a W/O emulsion with a particle size of 10 to 150 nm,

(c) adding the W/O emulsion in an aqueous phase with stirring to form a double emulsion, and

(d) removing the organic solvent from the double emulsion, thereby producing a liposome.

26. (New) The method according to claim 25, wherein the particle size of the W/O emulsion is 30 to 100 nm.

27. (New) The method according to claim 25, wherein the step (a) further comprises dissolving cholesterol in the water-immiscible organic solvent.